LYEL

$15.4343.27%4.66

Dopo l'orario di chiusura: 15.74+0.31 +2.01%

Lyell Immunopharma Inc (LYEL)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$10.77

Aprire:

$12.09

Volume 24 ore:

1,100,515

Volume relativo:

5.22

Capitalizzazione di mercato:

$378.11M

Reddito:

$31,000

Utile/perdita netta:

-$246.41M

Rapporto P/E:

EPS:

-$12.74

Flusso di cassa netto:

-$134.42M

1W Prestazione:

+41.17%

1M Prestazione:

+66.63%

6M Prestazione:

-25.53%

1Y Prestazione:

-3.26%

Intervallo 1D:

$12.09$16.73

Intervallo di 1 settimana:

$10.56$16.73

Portata 52W:

$7.20$45.00

Profilo aziendale di Lyell Immunopharma Inc (LYEL)

Nome

Lyell Immunopharma Inc

Settore

Healthcare

Industria

Biotechnology

Telefono

650 695-0677

Indirizzo

201 HASKINS WAY, SOUTH SAN FRANCISCO, USA

Dipendente

161

Prossima data di guadagno

2026-11-11

Ultimi documenti SEC

SEC

Discussioni di LYEL su X

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Lyell Immunopharma Inc Azioni (LYEL) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-08-06	Iniziato	Stifel	Buy
2026-07-22	Iniziato	B. Riley Securities	Buy
2026-05-01	Iniziato	Robert W. Baird	Outperform
2026-04-10	Iniziato	Needham	Buy
2026-03-09	Iniziato	Citizens	Mkt Outperform
2025-12-09	Aggiornamento	H.C. Wainwright	Neutral → Buy
2024-10-30	Downgrade	BofA Securities	Buy → Underperform
2024-06-27	Downgrade	H.C. Wainwright	Buy → Neutral
2023-08-28	Downgrade	JP Morgan	Overweight → Neutral
2022-11-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-11-11	Downgrade	Goldman	Buy → Neutral
2022-10-17	Iniziato	H.C. Wainwright	Buy
2021-07-12	Iniziato	BofA Securities	Buy
2021-07-12	Iniziato	Goldman	Buy
2021-07-12	Iniziato	JP Morgan	Overweight
2021-07-12	Iniziato	Morgan Stanley	Overweight

Lyell Immunopharma Inc Azioni (LYEL) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	0.04	0.06	0.13	84.68	10.65
Research and development USD (M)	-	-	182.95	159.19	138.69
Operating expenses USD (M)	269.44	358.82	247.14	271.74	225.43
Operating income USD (M)	-269.40	-358.76	-247.01	-187.06	-214.78
Income before tax USD (M)	-	-	0.13	84.68	10.65
Income tax expense USD (M)	0.00	-	-	-	-
Net income USD (M)	-274.45	-342.99	-234.63	-183.12	-250.22
Basic EPS USD/shares	-16.06	-1.31	-0.93	-0.74	-1.84
Diluted EPS USD/shares	-16.06	-1.31	-0.93	-0.74	-1.84
Basic weighted shares shares (M)	17.09	261.48	250.98	247.08	0.14
Diluted weighted shares shares (M)	17.09	261.48	250.98	247.08	0.14

Lyell Immunopharma Inc Azioni (LYEL) insider trading

Aguirre Jarrad MattieuOct 12 '26
Chief Medical Officer
Transazione
Sale
Costo
$8.63
#Azioni
422
Valore ($)
3,642
#Azioni Totale
19,857
Shook DavidSep 10 '26
Chief Medical Officer
Transazione
Sale
Costo
$12.70
#Azioni
500
Valore ($)
6,350
#Azioni Totale
20,423
Hill Stephen J.Aug 21 '26
Chief Operating Officer
Transazione
Sale
Costo
$15.54
#Azioni
989
Valore ($)
15,369
#Azioni Totale
16,816
Seely LynnAug 21 '26
President and CEO
Transazione
Sale
Costo
$15.54
#Azioni
9,589
Valore ($)
149,013
#Azioni Totale
63,899
Lee Gary K.Aug 21 '26
Chief Scientific Officer
Transazione
Sale
Costo
$15.54
#Azioni
1,457
Valore ($)
22,642
#Azioni Totale
16,220
Hill Stephen J.Aug 10 '26
Chief Operating Officer
Transazione
Sale
Costo
$14.34
#Azioni
89
Valore ($)
1,276
#Azioni Totale
17,805
Seely LynnAug 10 '26
President and CEO
Transazione
Sale
Costo
$14.34
#Azioni
390
Valore ($)
5,593
#Azioni Totale
73,488
Lee Gary K.Aug 10 '26
Chief Scientific Officer
Transazione
Sale
Costo
$14.34
#Azioni
131
Valore ($)
1,879
#Azioni Totale
17,677
Bulis Veronica SanchezAug 10 '26
VP, Corporate Controller
Transazione
Sale
Costo
$14.34
#Azioni
621
Valore ($)
8,905
#Azioni Totale
14,799
Innovative Cellular TherapeutiJul 17 '26
10% Owner
Transazione
Sale
Costo
$13.70
#Azioni
10
Valore ($)
137
#Azioni Totale
2,857,480

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Aguirre Jarrad Mattieu	Chief Medical Officer	Oct 12 '26	Sale	$8.63	422	3,642	19,857
Shook David	Chief Medical Officer	Sep 10 '26	Sale	$12.70	500	6,350	20,423
Hill Stephen J.	Chief Operating Officer	Aug 21 '26	Sale	$15.54	989	15,369	16,816
Seely Lynn	President and CEO	Aug 21 '26	Sale	$15.54	9,589	149,013	63,899
Lee Gary K.	Chief Scientific Officer	Aug 21 '26	Sale	$15.54	1,457	22,642	16,220
Hill Stephen J.	Chief Operating Officer	Aug 10 '26	Sale	$14.34	89	1,276	17,805
Seely Lynn	President and CEO	Aug 10 '26	Sale	$14.34	390	5,593	73,488
Lee Gary K.	Chief Scientific Officer	Aug 10 '26	Sale	$14.34	131	1,879	17,677
Bulis Veronica Sanchez	VP, Corporate Controller	Aug 10 '26	Sale	$14.34	621	8,905	14,799
Innovative Cellular Therapeuti	10% Owner	Jul 17 '26	Sale	$13.70	10	137	2,857,480

Lyell Immunopharma Inc Borsa (LYEL) Ultime notizie

Oct 29, 2026

Lyell Immunopharma stock: CMO sold 422 shares for taxes - ad-hoc-news.de

Oct 29, 2026

Oct 15, 2026

Lyell Immunopharma CMO sells 422 shares: USD 40.86 target for Lyell Immunopharma stock - ad-hoc-news.de

Oct 15, 2026

Oct 13, 2026

Lyell Immunopharma CMO sells $3,641 in shares for tax withholding - Investing.com

Oct 13, 2026

Form 4 Lyell Immunopharma Inc: Jarrad Mattieu Aguirre (Chief Medical Officer) For: 12 October - Investing.com Nigeria

Oct 13, 2026

Lyell Immunopharma CMO sells $3,641 in shares for tax withholding By Investing.com - Investing.com Nigeria

Oct 13, 2026

Form 4 Lyell Immunopharma Inc: Jarrad Mattieu Aguirre (Chief Medical Officer) For: 12 October - Investing.com Canada

Oct 13, 2026

Lyell Immunopharma CMO sells $3,641 in shares for tax withholding By Investing.com - Investing.com UK

Oct 13, 2026

An automatic tax-cover sale leaves Lyell Immunopharma (LYEL) medical chief holding 19,857 shares. - Stock Titan

Oct 13, 2026

Sep 25, 2026

Lyell Immunopharma Inc (NASDAQ: LYEL) Share Price, LYEL Stock News, LYEL Share Price & Updates - kalkine.ca

Sep 25, 2026

Sep 21, 2026

Lyell Immunopharma (Nasdaq:LYEL) - Stock Analysis - Simply Wall Street

Sep 21, 2026

Sep 11, 2026

H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com Canada

Sep 11, 2026

H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy - Investing.com

Sep 11, 2026

H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com India

Sep 11, 2026

Lyell Immunopharma CMO David Shook sells $6,350 in shares By Investing.com - Investing.com India

Sep 11, 2026

Lyell completes LYL273 manufacturing transfer, eyes 2027 FDA meeting By Investing.com - Investing.com Nigeria

Sep 11, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 11, 2026

Sep 10, 2026

Lyell Immunopharma CMO David Shook sells $6,350 in shares By Investing.com - Investing.com South Africa

Sep 10, 2026

Lyell Immunopharma CMO David Shook sells $6,350 in shares - Investing.com

Sep 10, 2026

Lyell Immunopharma CMO David Shook sells $6,350 in shares By Investing.com - Investing.com Canada

Sep 10, 2026

Lyell Immunopharma CMO David Shook sells $6,350 in shares By Investing.com - Investing.com UK

Sep 10, 2026

Lyell Immunopharma (LYEL) CMO discloses stock, RSUs and option awards - Stock Titan

Sep 10, 2026

Lyell completes LYL273 manufacturing transfer, eyes 2027 FDA meeting - investing.com

Sep 10, 2026

Lyell Immunopharma advances LYL273 CAR T program - TipRanks

Sep 10, 2026

An experimental cancer treatment has moved to a manufacturing center. Lyell expects data in 2027. - Stock Titan

Sep 10, 2026

Sep 09, 2026